What Percent of Koalas Have Chlamydia?

Chlamydia infection rates in wild koalas range from essentially zero to roughly two-thirds of a population, depending on where in Australia you look. Across the most-studied populations in Queensland and parts of South Australia, somewhere around a third to half of koalas test positive for the bacterium Chlamydia pecorum. But that headline number hides two complications that matter enormously for koala conservation: prevalence swings wildly between regions, and being infected is not the same as being sick.

How Prevalence Differs Across Australia

There is no single “koala chlamydia rate.” Infection prevalence depends on the population, the region, the testing method, and when the survey was done. In Southeast Queensland, one study tracking koalas across two geographically separated habitats found an overall infection rate of about 32%, but the northern study area had a rate of 46% while the southern area sat at 17%.¹ In South Australia’s Mount Lofty Ranges, nearly 47% of surveyed koalas tested positive by PCR.² And in Victoria’s Greater Geelong region, a recent study detected C. pecorum in about two-thirds of scat samples collected from two koala populations.³

At the other extreme, Kangaroo Island off the coast of South Australia has been demonstrated to be free of C. pecorum infection entirely.² That island’s koalas descend from a small number of introduced animals that apparently never carried the bacterium, and their geographic isolation has kept the population clean. The contrast with mainland populations less than 150 kilometers away underscores just how much local history and connectivity shape infection rates.

The Gap Between Infection and Disease

One of the most important distinctions in koala chlamydia research is that many infected animals never develop visible illness. In the Mount Lofty Ranges population where nearly 47% of koalas carried C. pecorum, only about 4% showed overt clinical disease.² That is a striking ratio: more than ten infected koalas for every one that was visibly sick. In Queensland populations, the picture looks worse. The Southeast Queensland study found that 57% of infected koalas exhibited clinical disease, and overall disease prevalence ran at about 24%.¹ Northern populations in Queensland have historically had higher rates of overt disease compared to their southern counterparts, and researchers have been trying for years to figure out why.

Part of the answer seems to involve the strain of chlamydia. Not all C. pecorum strains behave the same way. Research tracking chlamydial genotypes in two Queensland populations found that certain sequence types were significantly more common in koalas whose infections progressed to disease, while other sequence types were more prevalent in koalas that resolved their infections or remained chronically infected without symptoms.⁴ It is also worth noting that koalas can carry a second species, Chlamydia pneumoniae, but early research found that none of the C. pneumoniae-infected koalas showed clinical signs, pointing to C. pecorum as the more dangerous pathogen.⁵

What Chlamydia Actually Does to a Koala

When chlamydial infection does progress to disease, it typically strikes two areas: the eyes and the urogenital tract. Ocular disease progresses through recognizable stages. Early on, a koala develops inflamed, reddened conjunctiva. If untreated, this can advance to chronic keratoconjunctivitis with discharge, swelling, and eventually corneal scarring that can cause partial or complete blindness.⁶ For an arboreal animal that relies on vision to navigate tree canopies and judge distances, even moderate vision impairment can be deadly.

Urogenital disease often manifests as a condition wildlife carers call “wet bottom,” a visible staining of the rump fur from urinary incontinence caused by infection of the urinary tract. Though wet bottom is closely associated with chlamydial infection, it can also appear in koalas that test negative for C. pecorum, meaning other microbes are sometimes responsible.⁷ So a koala presenting with wet bottom is not automatically chlamydia-positive, though in most populations chlamydia is the leading cause.

Fertility, Reproductive Cysts, and Population Decline

The most devastating long-term consequence of chlamydial disease in female koalas is reproductive damage. The bacterium infects the mucosal lining of the reproductive tract, triggering inflammation and fibrosis that can lead to ovarian bursal cysts. These cysts effectively render females infertile.⁸ Research into the underlying mechanism has found that key proteins responsible for maintaining the structural integrity of epithelial tissue in the reproductive tract are significantly reduced in cystic tissue compared to healthy tissue, suggesting the damage may be permanent.⁹

When a significant fraction of breeding-age females in a population becomes infertile, the population’s ability to replace itself erodes. Multiple koala populations across Southeast Queensland have experienced serious declines, with chlamydia identified as a substantial contributor.¹⁰ Habitat loss and vehicle strikes get more media attention, but in some regions the steady sterilization of females by chlamydia is the bigger driver of decline.

Koala Retrovirus and Why It Makes Things Worse

Koalas face an unusual double burden: they carry an endogenous retrovirus called KoRV that is embedded in their genome. Most koalas in northern Australia are positive for the original strain, KoRV-A, which appears to be relatively benign on its own. But a more recently emerged variant, KoRV-B, has been linked to significantly worse chlamydial disease outcomes. A study of wild koalas found that testing positive for KoRV-B was significantly associated with having chlamydial disease, even after accounting for chlamydial infection levels and strain type.¹¹

The proposed mechanism is immunosuppression. Higher KoRV viral loads in blood plasma were the single best predictor of disease across a range of pathologies: the predicted probability of a koala having disease symptoms climbed from about 25% to over 85% across the observed range of viral loads, and the probability of C. pecorum infection rose from about 40% to over 80%.¹² In other words, higher KoRV replication seems to weaken the immune system enough that chlamydial infections are more likely to take hold and progress to illness. Research into the relationship between KoRV load and stress hormones found that the immune suppression is more likely driven by viral replication killing or disrupting immune cells rather than by stress hormones alone.¹³

The Role of Stress and Habitat Quality

Environmental stress does still matter, just not always through the straightforward pathway people assume. Koalas living in fragmented, urbanized habitats face threats from dogs, cars, and loss of food trees, all of which elevate physiological stress. Research on rescued koalas from different habitat types found significant interactions between location, the type of stressor, and clinical diagnosis when measuring stress hormone metabolites.¹⁴ During extreme heat and drought, koalas showed signs of immune suppression at the gene-expression level, with upregulated stress pathways and reduced adaptive immune gene expression. Interestingly, these immune changes appeared even before obvious disease symptoms did, suggesting that immune markers are earlier warning signals of trouble than visible chlamydial disease.¹⁵

The practical takeaway is that chlamydia prevalence rates are not fixed properties of koala biology. They reflect a web of interacting factors: the bacterial strains circulating in a region, the koalas’ retroviral burden, habitat quality, climate stress, and the animals’ immune genetics. A population in pristine, connected forest with low KoRV-B prevalence can carry C. pecorum at moderate rates and mostly keep the disease in check. The same infection rate in a fragmented, stressed population with high KoRV-B loads becomes a crisis.

Treatment in Practice

When sick koalas end up in wildlife hospitals, the standard treatment is antibiotics, but not all antibiotics work equally well. A comparison of five drugs used under consistent conditions at one Australian wildlife hospital found enormous differences in cure rates. Doxycycline was the clear winner at 97%, followed by chloramphenicol at 81%, enrofloxacin at 75%, florfenicol at 66%, and azithromycin at just 25%.¹⁶ Doxycycline has the added advantage of being available as a long-acting injectable, so koalas only need a subcutaneous dose once a week rather than daily oral medication, a big practical benefit for wild animals that do not cooperate with pill schedules.

Treatment duration matters too. Koalas given chloramphenicol for at least 28 days had substantially higher odds of survival compared to those treated for shorter courses.¹⁷ The trouble is that weeks of hospitalization for a wild koala are expensive and stressful for the animal. Even with treatment, about half of rehabilitated koalas in one long-term study survived after release, and all the post-release deaths occurred among koalas that had required medical intervention, not those admitted for non-medical reasons like orphaned joeys.¹⁸ A separate decade-long review at another facility found a similar roughly 50% release rate for chlamydia cases.¹⁹

Antibiotics also carry a hidden cost for koalas. These animals depend on specialized gut microbiomes to detoxify the eucalyptus leaves that make up their entire diet. Broad-spectrum antibiotics can disrupt those microbial communities, potentially causing appetite loss and further health problems during recovery. This is one reason researchers have been so eager to find alternatives to treatment-by-treatment rescue.

Where Vaccine Development Stands

A chlamydia vaccine for koalas has been the holy grail of koala conservation medicine for more than a decade. The most encouraging results come from a long-term field trial of a vaccine based on the major outer membrane protein (MOMP) of C. pecorum. Over ten years of tracking 680 koalas with five vaccine trials, vaccinated animals had significantly lower disease incidence and a 64% reduction in chlamydial mortality.²⁰ That is a genuinely promising result, but it comes with caveats that have become clearer from other trials.

A synthetic peptide version of the MOMP vaccine tested in a wild population with high existing infection prevalence found no significant effect on chlamydial shedding, infection loads, or even antibody levels.²¹ Another field evaluation found that while vaccination did stimulate an immune response, including specific antibody production and inflammatory signaling, this immunological boost did not translate into any measurable effect on disease or bacterial shedding in the study populations.²² The vaccine appeared unable to boost immune responses in koalas that already carried the infection from natural exposure.

The pattern emerging from these studies is that vaccination works best as prevention rather than treatment. Vaccinating naive or lightly infected populations could protect them before chlamydia becomes entrenched. But rolling out a vaccine to a population that is already heavily infected, where most animals have prior exposure and many already carry the bacterium, is a much harder proposition. The successful long-term trial likely benefited from catching koalas relatively early, while the unsuccessful synthetic-peptide trial was working with a population where the horse had already left the barn.

Genetic Susceptibility and What It Means for the Species

Not all koalas respond to chlamydia the same way, and part of that variation is heritable. An analysis using genetic data from thousands of markers estimated the heritability of chlamydia status at about 0.11, meaning that roughly 11% of the variation in whether a koala has chlamydia can be attributed to inherited genetic differences.²³ That is a modest but real genetic contribution. The same study found no evidence of inbreeding depression for chlamydia susceptibility, which was a surprise given how genetically bottlenecked some koala populations are.

The existence of heritable resistance raises the possibility that natural selection could, over enough generations, shift koala populations toward greater tolerance of the bacterium. But “enough generations” is a long time for an animal that breeds slowly. A female koala typically produces one joey per year at best, and chlamydial infertility is removing breeding females from the gene pool faster than selection can act. Conservation managers cannot afford to wait for evolution and are instead trying to maintain genetic diversity through habitat connectivity, translocation programs, and the vaccination approaches described earlier.

Diagnosing Chlamydia in Wild Populations

Surveying chlamydia prevalence in koalas used to require capturing individual animals and collecting swabs from their eyes or urogenital openings, a procedure that is stressful, labor-intensive, and logistically difficult across large areas of bushland. The development of non-invasive scat-based testing, as used in the Greater Geelong study that detected C. pecorum in about two-thirds of collected samples, is making broad population screening more feasible.³

For clinical settings, a rapid point-of-care test using a technique called loop-mediated isothermal amplification has been developed that can detect C. pecorum without the need for complex laboratory equipment. In validation testing, it showed perfect specificity with no false positives across dozens of non-target pathogens, and its results completely matched those of the gold-standard laboratory test on clinical swabs from wildlife hospitals.²⁴ Faster diagnosis means wildlife carers can start appropriate treatment sooner and avoid wasting time on antibiotics for koalas whose symptoms have a different cause entirely.

These diagnostic advances also matter for population management. If you can screen a population quickly and cheaply, you can identify which populations are infection-free and prioritize protecting them from introduction. Kangaroo Island’s chlamydia-free status, for instance, is an asset worth guarding. Translocating mainland koalas to island populations without proper screening could introduce the pathogen to a naive group with no acquired immunity, potentially triggering a disease wave far worse than what mainland populations experience.